60 DEGREES PHARMACEUTICALS, INC. 8-K

What Happened 60 Degrees Pharmaceuticals, Inc. filed an 8-K reporting that its Board of Directors appointed Eric Francois as a director effective May 13, 2026. Mr. Francois is a strategic financial executive with over 20 years of experience in healthcare and life sciences and currently serves as an independent director of CERo Therapeutics Holdings, Inc. (Nasdaq: CERO).

Key Details

• Appointment effective date: May 13, 2026.
• Background: Former Managing Director in Healthcare Investment Banking at Raymond James and Credit Suisse; former CFO of SCYNEXIS, Inc. (Nasdaq: SCYX).
• Capital raised: As CFO at SCYNEXIS, he helped raise over $300 million to support FDA approval and commercial launch.
• Governance and conflicts: No arrangements or understandings related to his appointment; no family relationships with company officers or directors; no reportable related-party transactions under Item 404(a). He will receive the company’s standard non-employee director compensation.

Why It Matters Adding a director with deep healthcare finance, capital markets and industry experience may strengthen the company’s board governance and access to capital markets expertise. For investors, the appointment signals the board is bringing on proven financial and transaction experience that could aid strategic, financing, or M&A activities; the filing contains no indication of related-party issues or special compensation beyond standard director pay.